<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32532288</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1172</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>Orphanet journal of rare diseases</Title><ISOAbbreviation>Orphanet J Rare Dis</ISOAbbreviation></Journal><ArticleTitle>Costs of illness in amyotrophic lateral sclerosis (ALS): a cross-sectional survey in Germany.</ArticleTitle><Pagination><StartPage>149</StartPage><MedlinePgn>149</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">149</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13023-020-01413-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder. Consequently, patients undergo a multidisciplinary treatment that often requires intensive use of medical resources. This study provides an estimate on the cost of illness depending on the clinical severity while also analysing the patients' health-related quality of life.</AbstractText><AbstractText Label="METHODS">Primary data from patients and caregivers was collected through a standardised questionnaire. Direct medical, direct non-medical and indirect costs were calculated using the latest German health economic guidelines. Patients were divided into five groups according to the King's staging system. Health-related quality of life was assessed using EuroQoL Group EQ-5D-5L&#x2122; questionnaire. Influencing factors on both total cost and quality of life were examined.</AbstractText><AbstractText Label="RESULTS">The mean annual total cost of illness was 78,256&#x20ac; per patient while the lifetime cost per patient was estimated at 246,184&#x20ac;. The prevalence based total burden yearly therefore was 519,776,352&#x20ac; in Germany. Nearly half of the costs were attributable to informal care. With increase of the clinical severity stage, costs rose and quality of life decreased. The score of the revised Amyotrophic Laterals Sclerosis Functional Rating Scale was identified as one major influencing factor on total costs, while subjective impairment in daily activities and classification into a care level as opposed to having no care level influenced patients' quality of life.</AbstractText><AbstractText Label="CONCLUSION">It is essential to understand the socioeconomic burden of a disease. These data can be used to improve patient care standards and quality of life while also serving as a basis for cost-benefit analyses during the approval process of new treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sch&#xf6;nfelder</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, OE 7210, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osmanovic</LastName><ForeName>Alma</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, OE 7210, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;schen</LastName><ForeName>Lars Hendrik</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, OE 7210, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, OE 7210, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreiber-Katz</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-5621-4487</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, OE 7210, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany. Schreiber-Katz.Olivia@mh-hannover.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Orphanet J Rare Dis</MedlineTA><NlmUniqueID>101266602</NlmUniqueID><ISSNLinking>1750-1172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="N">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Cost of illness (COI)</Keyword><Keyword MajorTopicYN="N">Disease cost</Keyword><Keyword MajorTopicYN="N">Health care burden</Keyword><Keyword MajorTopicYN="N">Health-related quality of life (HRQoL)</Keyword><Keyword MajorTopicYN="N">King&#x2019;s staging system</Keyword><Keyword MajorTopicYN="N">Socioeconomic burden</Keyword></KeywordList><CoiStatement>The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: ES reports no conflicts of interest. AO has received honoraria as a speaker/consultant from the German Neuromuscular Society &#x201c;Deutsche Gesellschaft fuer Muskelkranke (DGM e.V.)&#x201d; and Biogen GmbH. She has received academic research support by PRACTIS &#x2013; Clinician Scientist Program of Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3&#x2013;1). LHM reports no conflicts of interest. SP has received grants by the German Neuromuscular Society (Deutsche Gesellschaft fuer Muskelkranke (DGM e.V.)), the Federal Ministry of Education and Research (BMBF), the German Israeli Foundation (GIF) for Scientific Research and Development and the EU Joint Programme for Neurodegenerative Disease Research (JPND). She has received speaking honoraria from Desitin Pharma, Biogen GmbH, Novartis and TEVA as well as fees for consulting from Biogen GmbH, Roche Pharma, Cytokinetics Inc. OSK has received honoraria as a speaker/consultant and/or funding for travel expenses from the German Neuromuscular Society (Deutsche Gesellschaft fuer Muskelkranke (DGM e.V.)), Novartis, Biogen GmbH and the Jain Foundation. She has received academic research support by the Ludwig-Maximilians-University of Munich, FoeFoLe program, Reg.-No. 747, 11/11&#x2013;05/13, and the Hannover Medical School Young Faculty Program, 2018&#x2013;2020. She has received research support from the Friedrich-Baur-GmbH, Burgkunstadt 12/13&#x2013;12/15 and the German Neuromuscular Society "Deutsche Gesellschaft fuer Muskelkranke (DGM e.V.), 2019&#x2013;2020.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32532288</ArticleId><ArticleId IdType="pmc">PMC7291655</ArticleId><ArticleId IdType="doi">10.1186/s13023-020-01413-9</ArticleId><ArticleId IdType="pii">10.1186/s13023-020-01413-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, Pagani W, Lodin D, Orozco G, Chinea A. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6:171. doi: 10.4103/2152-7806.169561.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2152-7806.169561</ArticleId><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster LA, Salajegheh MK. Motor neuron disease: pathophysiology, diagnosis, and management. Am J Med. 2019;132(1):32&#x2013;37. doi: 10.1016/j.amjmed.2018.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2018.07.012</ArticleId><ArticleId IdType="pubmed">30075105</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A, Peter R, Erhardt S, Lul&#xe9; D, Rothenbacher D, Ludolph A, Nagel G. Epidemiology of amyotrophic lateral sclerosis in southern Germany. J Neurol. 2017;264(4):749&#x2013;757. doi: 10.1007/s00415-017-8413-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8413-3</ArticleId><ArticleId IdType="pubmed">28220290</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10(11):661&#x2013;670. doi: 10.1038/nrneurol.2014.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2012;3:CD001447. doi: 10.1002/14651858.CD001447.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7&#x2013;8):610&#x2013;617. doi: 10.3109/21678421.2014.959024.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the quality standards Subcommittee of the American Academy of neurology. Neurology. 2009;73(15):1218&#x2013;1226. doi: 10.1212/WNL.0b013e3181bc0141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bc0141</ArticleId><ArticleId IdType="pmc">PMC2764727</ArticleId><ArticleId IdType="pubmed">19822872</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobson EV, McDermott CJ. Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2016;12(9):526&#x2013;538. doi: 10.1038/nrneurol.2016.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.111</ArticleId><ArticleId IdType="pubmed">27514291</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5(2):140&#x2013;147. doi: 10.1016/S1474-4422(05)70326-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70326-4</ArticleId><ArticleId IdType="pubmed">16426990</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Bottacchi E, Buffa C, Mutani R, Mora G. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77(8):948&#x2013;950. doi: 10.1136/jnnp.2005.083402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.083402</ArticleId><ArticleId IdType="pmc">PMC2077622</ArticleId><ArticleId IdType="pubmed">16614011</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, Habeeb-Louks EM, Kennedy A, Cwik VA. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014;49(3):431&#x2013;438. doi: 10.1002/mus.23942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.23942</ArticleId><ArticleId IdType="pubmed">23836444</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Bastida J, Perestelo-P&#xe9;rez L, Mont&#xf3;n-Alvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler. 2009;10(4):237&#x2013;243. doi: 10.1080/17482960802430781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802430781</ArticleId><ArticleId IdType="pubmed">18821088</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J, An JW, Oh S, Oh KW, Kim JA, Lee JS, Kim SH. Socioeconomic costs of amyotrophic lateral sclerosis according to staging system. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3&#x2013;4):202&#x2013;208. doi: 10.3109/21678421.2014.999791.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.999791</ArticleId><ArticleId IdType="pubmed">25646865</ArticleId></ArticleIdList></Reference><Reference><Citation>Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schr&#xf6;der R, Heuss D, Vielhaber S, Mylius V, Kiefer R, Schrank B, Oertel WH, Dodel R. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257(1):15&#x2013;23. doi: 10.1007/s00415-009-5256-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-5256-6</ArticleId><ArticleId IdType="pubmed">19629566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, Shefner J. A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5&#x2013;6):291&#x2013;292. doi: 10.3109/21678421.2015.1049183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1049183</ArticleId><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber-Katz O, Klug C, Thiele S, Schorling E, Zowe J, Reilich P, Nagels KH, Walter MC. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014;9:210&#x2013;219. doi: 10.1186/s13023-014-0210-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-014-0210-9</ArticleId><ArticleId IdType="pmc">PMC4302713</ArticleId><ArticleId IdType="pubmed">25519771</ArticleId></ArticleIdList></Reference><Reference><Citation>Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, Walter MC, Nagels KH. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;11(1):58. doi: 10.1186/s13023-016-0424-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-016-0424-0</ArticleId><ArticleId IdType="pmc">PMC4857429</ArticleId><ArticleId IdType="pubmed">27145956</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III) J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21. doi: 10.1016/s0022-510x(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, Wijesekera L, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135(3):847&#x2013;852. doi: 10.1093/brain/awr351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr351</ArticleId><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, Turner MR, Leigh PN, Shaw CE, Al-Chalabi A. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS functional rating scale. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(3&#x2013;4):279&#x2013;284. doi: 10.3109/21678421.2014.897357.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.897357</ArticleId><ArticleId IdType="pubmed">24720420</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20(10):1727&#x2013;1736. doi: 10.1007/s11136-011-9903-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-011-9903-x</ArticleId><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig K. Graf von der Schulenburg JM, Greiner W. German Value Set for the EQ-5D-5L. Pharmacoeconomics. 2018;36(6):663&#x2013;674. doi: 10.1007/s40273-018-0615-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-018-0615-8</ArticleId><ArticleId IdType="pmc">PMC5954069</ArticleId><ArticleId IdType="pubmed">29460066</ArticleId></ArticleIdList></Reference><Reference><Citation>Krauth C. Methoden der Kostenbestimmung in der gesundheits&#xf6;konomischen evaluation [cost estimation methods in health economic evaluation] Gesundh &#xf6;kon Qual manag. 2010;15(5):251&#x2013;259. doi: 10.1055/s-0029-1245680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0029-1245680</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock JO, Brettschneider C, Seidl H, Bowles D, Holle R, Greiner W, K&#xf6;nig HH. Standardisierte Bewertungss&#xe4;tze aus gesellschaftlicher Perspektive f&#xfc;r die gesundheits&#xf6;konomische Evaluation. Baden-Baden: Nomos Verlagsgesellschaft; 2015.</Citation><ArticleIdList><ArticleId IdType="pubmed">25025287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bock JO, Brettschneider C, Seidl H, Bowles D, Holle R, Greiner W, K&#xf6;nig HH. Ermittlung standardisierter Bewertungss&#xe4;tze aus gesellschaftlicher Perspektive f&#xfc;r die gesundheits&#xf6;konomische evaluation [calculation of standardised unit costs from a societal perspective for health economic evaluation] Gesundheitswesen. 2015;77(1):53&#x2013;61. doi: 10.1055/s-0034-1374621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0034-1374621</ArticleId><ArticleId IdType="pubmed">25025287</ArticleId></ArticleIdList></Reference><Reference><Citation>Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B. Empirische Bewertungss&#xe4;tze in der gesundheits&#xf6;konomischen evaluation -- ein Vorschlag der AG Methoden der gesundheits&#xf6;konomischen evaluation (AG MEG) [empirical standard costs for health economic evaluation in Germany -- a proposal by the working group methods in health economic evaluation] Gesundheitswesen. 2005;67(10):736&#x2013;746. doi: 10.1055/s-2005-858698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2005-858698</ArticleId><ArticleId IdType="pubmed">16235143</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundesgesundheitsministerium. Pflegegrade. 2018. https://www.bundesgesundheitsministerium.de/pflegegrade.html. Accessed 11 December 2019.</Citation></Reference><Reference><Citation>Manjaly ZR, Scott KM, Abhinav K, Wijesekera L, Ganesalingam J, Goldstein LH, Janssen A, Dougherty A, Willey E, Stanton BR, Turner MR, Ampong M, Sakel M, Orrell RW, Howard R, Shaw CE, Leigh PN, Al-Chalabi A. The sex ratio in amyotrophic lateral sclerosis: a population based study. Amyotroph Lat Scler. 2010;11(5):439&#x2013;442. doi: 10.3109/17482961003610853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482961003610853</ArticleId><ArticleId IdType="pmc">PMC6485484</ArticleId><ArticleId IdType="pubmed">20225930</ArticleId></ArticleIdList></Reference><Reference><Citation>Bundesgesundheitsministerium. Gesetzliche Krankenversicherung: Mitglieder, mitversicherte Angeh&#xf6;rige und Krankenstand, Jahresdurchschnitt 2018. 2019. https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/Statistiken/GKV/Mitglieder_Versicherte/KM1_JD_2018.pdf. Accessed 24 June 2019.</Citation></Reference><Reference><Citation>Statistisches Bundesamt. Bev&#xf6;lkerung auf Grundlage des Zensus 2011 nach Geschlecht und Staatsangeh&#xf6;rigkeit im Zeitverlauf. 2019. https://www.destatis.de/DE/Presse/Pressemitteilungen/2019/06/PD19_244_12411.html. Accessed 24 June 2019.</Citation></Reference><Reference><Citation>Pharmacoeconomic Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019.</Citation></Reference><Reference><Citation>Fiorentino G, Esquinas AM. Cost-effectiveness associated with amyotrophic lateral sclerosis: some questions and answers pending. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(3&#x2013;4):315&#x2013;316. doi: 10.1080/21678421.2017.1408126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1408126</ArticleId><ArticleId IdType="pubmed">29191046</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruis KL, Chernew ME, Brown DL. The cost-effectiveness of early noninvasive ventilation for ALS patients. BMC Health Serv Res. 2005;5:58. doi: 10.1186/1472-6963-5-58.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6963-5-58</ArticleId><ArticleId IdType="pmc">PMC1208883</ArticleId><ArticleId IdType="pubmed">16131401</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg G, Lowe S. Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature. Pharmacoeconomics. 2002;20(6):367&#x2013;387. doi: 10.2165/00019053-200220060-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-200220060-00002</ArticleId><ArticleId IdType="pubmed">12052096</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano H, Yasuda D, Fujimori K, Morimoto S, Takahashi S. Ropinirole, a new ALS drug candidate developed using iPSCs. Trends Pharmacol Sci. 2020;41(2):99&#x2013;109. doi: 10.1016/j.tips.2019.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2019.12.002</ArticleId><ArticleId IdType="pubmed">31926602</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella M, Ciotti C, Cohen-Tannoudji M, Biferi MG. Gene Therapy for ALS-A Perspective. Int J Mol Sci. 2019;20(18):4388. doi: 10.3390/ijms20184388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20184388</ArticleId><ArticleId IdType="pmc">PMC6771059</ArticleId><ArticleId IdType="pubmed">31500113</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpanini SM, Torvell M, Morgan BP. Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System. Front Immunol. 2019;10:362. doi: 10.3389/fimmu.2019.00362.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00362</ArticleId><ArticleId IdType="pmc">PMC6409326</ArticleId><ArticleId IdType="pubmed">30886620</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistisches Bundesamt. Gesundheitsausgaben im Jahr 2017. 2019. https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Gesundheitsausgaben/_inhalt.html. Accessed 24 June 2019.</Citation></Reference><Reference><Citation>Wetzstein M, Rommel A, Lange C. Informal caregivers - Germany&#x2019;s largest nursing service. 610 Medizin. Robert-Koch-Institut. GBE kompakt vol. 6 no. 3. 2016. 10.25646/3065.</Citation></Reference><Reference><Citation>Chi&#xf2; A, Gauthier A, Calvo A, Ghiglione P, Mutani R. Caregiver burden and patients' perception of being a burden in ALS. Neurology. 2005;64(10):1780&#x2013;1782. doi: 10.1212/01.WNL.0000162034.06268.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000162034.06268.37</ArticleId><ArticleId IdType="pubmed">15911811</ArticleId></ArticleIdList></Reference><Reference><Citation>Butterworth P, Pymont C, Rodgers B, Windsor TD, Anstey KJ. Factors that explain the poorer mental health of caregivers: results from a community survey of older Australians. Aust N Z J Psychiatry. 2010;44(7):616&#x2013;624. doi: 10.3109/00048671003620202.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00048671003620202</ArticleId><ArticleId IdType="pubmed">20560849</ArticleId></ArticleIdList></Reference><Reference><Citation>Schorling E, Thiele S, Gumbert L, Krause S, Klug C, Schreiber-Katz O, Reilich P, Nagels K, Walter MC. Cost of illness in Charcot-Marie-tooth neuropathy: results from Germany. Neurology. 2019;92(17):e2027&#x2013;e2037. doi: 10.1212/WNL.0000000000007376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007376</ArticleId><ArticleId IdType="pubmed">30918088</ArticleId></ArticleIdList></Reference><Reference><Citation>Whynes DK. Correspondence between EQ-5D health state classifications and EQ VAS scores. Health Qual Life Outcomes. 2008;6:94. doi: 10.1186/1477-7525-6-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-6-94</ArticleId><ArticleId IdType="pmc">PMC2588564</ArticleId><ArticleId IdType="pubmed">18992139</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S, Kollewe K, Ilsemann J, M&#xfc;ller-Heine A, Dengler R, Krampfl K, Petri S. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol. 2013;20(4):647&#x2013;654. doi: 10.1111/ene.12015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12015</ArticleId><ArticleId IdType="pubmed">23094606</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>